$ cat ./records/backed-the-first-field-release-of-gene-drive-mosquitoes-to-fight--2021.txt
Backed the first field release of gene-drive mosquitoes to fight malaria in Africa
[RECORD.TXT] · cat --full
The Gates Foundation funded Target Malaria, a research consortium that conducted the first sanctioned field releases of genetically modified mosquitoes in Africa — in Burkina Faso and Mali — with the goal of suppressing Anopheles gambiae populations and reducing malaria transmission. The program developed both sterile male mosquitoes for immediate population suppression and gene-drive mosquitoes designed to spread a fertility-reducing gene through wild populations over successive generations. It represents one of the most ambitious genetic interventions in conservation and public health history.
Source: https://targetmalaria.org/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Published 'How to Avoid a Climate Disaster' — a #1 New York Times bestseller
Next →
Gates Foundation funding led to WHO approval of the world's first malaria vaccine
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.